Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LA-HCM: Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy
NCT07202897Phase 3Recruiting
- Sponsor
- CHU Rennes
- Start
- Jan 2026
- Primary completion
- Jan 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rivaroxaban in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by CHU Rennes. Primary endpoint: Composite of all-cause death, myocardial infarction, stroke and systemic embolism at 2 years. Started Jan 2026; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT07202897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07202897.